National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

House Dust Mite Extract (Acarizax ®) for Allergic Rhinitis. HTA ID: 20015

House Dust Mite extract (Acarizax®) is indicated in adult patients (18-65 years) diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.


NCPE Assessment Process Complete
Rapid review commissioned 12/03/2020
Rapid review completed 30/04/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract (Acarizax ®) compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.